Budget Impact Analysis of Ustekinumab for the Treatment of Moderate to Severe Crohn’s Disease from a Brazilian Private Payer Perspective
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.559
https://www.valueinhealthjournal.com/article/S1098-3015(18)30859-3/fulltext
Section Title :
Section Order :
1352
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30859-3&doi=10.1016/j.jval.2018.04.559